Antitumour activity of the novel flavonoid oncamex in preclinical breast cancer models
MetadataShow full item record
Background: The natural polyphenol myricetin induces cell cycle arrest and apoptosis in preclinical cancer models. We hypothesised that myricetin-derived flavonoids with enhanced redox properties, improved cell uptake and mitochondrial targeting might have increased potential as antitumour agents. Methods: We studied the effect of a second-generation flavonoid analogue, Oncamex, in a panel of 7 breast cancer cell lines, applying western blotting, gene expression analysis, fluorescence microscopy, and immunohistochemistry to xenograft tissue to investigate its mechanism of action. Results: Proliferation assays showed that Oncamex: treatment for 8 h reduced cell viability and induced cytotoxicity and apoptosis, concomitant with increased caspase activation. Microarray analysis showed that Oncamex was associated with changes in expression of genes controlling cell cycle and apoptosis . Fluorescence microscopy showed the compound’s mitochondrial targeting and ROS-modulating properties, inducing superoxide production at concentrations associated with anti-proliferative effects. A preliminary in vivo study in mice implanted with the MDA-MB-231 breast cancer xenograft showed that Oncamex inhibited tumour growth, reduced tissue viability and Ki-67 proliferation, with no overall systemic toxicity. Conclusion: Oncamex is a novel flavonoid capable of specific mitochondrial delivery and redox modulation. It has shown antitumour activity in preclinical models of breast cancer, supporting the potential of this prototypic candidate for its continued development as an anticancer agent.
Martínez-Pérez , C , Ward , C , Turnbull , A K , Mullen , P , Cook , G , Meehan , J , Jarman , E J , Thomson , P I T , Campbell , C J , McPhail , D , Harrison , D J & Langdon , S P 2016 , ' Antitumour activity of the novel flavonoid oncamex in preclinical breast cancer models ' British Journal of Cancer , vol 114 , no. 8 , pp. 905-916 . DOI: 10.1038/bjc.2016.6
British Journal of Cancer
This work is licensed under the Creative Commons Attribution-Non-Commercial-Share Alike 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
We thank SULSA (Scottish Universities Life Science Alliance) for supporting this project through a SULSA BioSkape Industry PhD Studentship and Antoxis Limited for providing additional funding. We also thank the 7th Framework Programme of the European Union (METOXIA project; HEALTH-F2-2009-222741) for support.
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Showing items related by title, author, creator and subject.
Cell population heterogeneity and evolution towards drug resistance in cancer : biological and mathematical assessment, theoretical treatment optimisation Chisholm, Rebecca H.; Lorenzi, Tommaso; Clairambault, Jean (2016-11) - Journal articleBackground. Drug-induced drug resistance in cancer has been attributed to diverse biological mechanisms at the individual cell or cell population scale, relying on stochastically or epigenetically varying expression of ...
Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS) : study protocol for a randomized controlled trial Sullivan, F. M.; Farmer, Eoghan; Mair, Frances S.; Treweek, Shaun; Kendrick, Denise; Jackson, Cathy; Robertson, Chris; Briggs, Andrew; McCowan, Colin; Bedford, Laura; Young, Ben; Vedhara, Kavita; Gallant, Stephanie; Littleford, Roberta; Robertson, John; Sewell, Herb; Dorward, Alistair; Sarvesvaran, Joseph; Schembri, Stuart (2017-03-11) - Journal articleBackground: Lung cancer is the most common cause of cancer related death worldwide. The majority of cases are detected at a late stage when prognosis is poor. The EarlyCDT®-Lung Test detects autoantibodies to abnormal cell ...
Macnamara, Cicely Krystyna; Eftimie, Raluca (2015-07-21) - Journal articleThe main priority when designing cancer immuno-therapies has been to seek viable biological mechanisms that lead to permanent cancer eradication or cancer control. Understanding the delicate balance between the role of ...